Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has been trending somewhat positive on Wednesday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MYOS RENS Technology earned a news impact score of 0.06 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0280758382023 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, ValuEngine downgraded MYOS RENS Technology from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th.
MYOS RENS Technology (NASDAQ MYOS) opened at $1.33 on Wednesday. MYOS RENS Technology has a one year low of $1.02 and a one year high of $6.98.
TRADEMARK VIOLATION WARNING: “MYOS RENS Technology (MYOS) Getting Somewhat Positive News Coverage, Report Finds” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thestockobserver.com/2017/11/15/myos-rens-technology-myos-getting-somewhat-positive-news-coverage-report-finds.html.
MYOS RENS Technology Company Profile
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.